Navigation Links
Oncologists in the United States and Europe Indicate that Novel Chemotherapies Hold the Most Near-Term Promise for Improving Outcomes in Soft Tissue Sarcoma
Date:1/29/2013

BURLINGTON, Mass., Jan. 29, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, although interviewed oncologists in the United States and Europe would like to see a future of personalized medicine targeting different soft tissue sarcoma subtypes, they believe that it is in fact novel chemotherapies that hold the most near-term promise for improving outcomes in this highly fragmented indication.

According to Niche Markets and Rare Diseases: Soft Tissue Sarcoma, the clinical pipeline for the disease is relatively sparse and chemotherapy remains the backbone of current treatment. Additionally, most late-stage research focuses on developing novel chemotherapeutic agents or new formulations of chemotherapy drugs with proven efficacy. There are only a few agents in Phase III clinical trials and the majority are chemotherapeutic agents, while considerably more therapies are in mid-stage development and, depending on data, regulators may be open to considering a filing based only on Phase II results.

Initial clinical trials typically position these agents in refractory populations, where the barrier to gaining regulatory approval is relatively low. However, expansion into first-line populations is underway for a number of novel agents in development. Decision Resources forecasts that four agents will launch for soft tissue sarcoma between now and 2018 – palifosfamide (Ziopharm's Zymaphos), eribulin (Eisai's Halaven), crizotinib (Pfizer's Xalkori) and Threshold Pharmaceuticals' TH-302.

"Although we believe that palifosfamide will gain approval for the treatment of soft tissue sarcoma, it will likely not have a significant impact on overall survival outcomes for patients, being largely equivalent to ifosfamide in this regard, although palifosfamide will demonstrate superior progression-free survival over doxorubicin alone," said Decision Resources Therapy Leader of Oncology Joanne Graham, Ph.D. "The key advantages of palifosfamide will be reduced neurotoxicity and improved ease of administration, especially once the oral capsule is available. It's anticipated that the improved convenience over ifosfamide—namely, reduced hospital stay and alleviation of the need for hydration—will offset the inevitable higher price of palifosfamide and will drive high uptake, especially once it becomes available in Europe."  

About Soft Tissue Sarcoma

Soft Tissue Sarcoma is offered as part of Decision Resources' Niche Markets and Rare Diseases service. Each report assesses opportunity in a select drug market across the United States, France, Germany, Italy, Spain and the United Kingdom. The report provides detailed coverage of patient populations, current therapies, unmet needs and emerging therapies, and includes primary research with country-specific thought leaders.

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.

About Decision Resources Group

Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.


'/>"/>
SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. ASCO Impact Report From Encuity Research Indicates Oncologists Are Likely to Shift Patient Treatment Plans
2. Oncologists restrict pharmaceutical sales rep access at accelerating rates
3. Cardinal Health Specialty Solutions, Health Alliance Plan Work With Michigan Oncologists to Improve Quality, Curb Costs of Cancer Care
4. Survey of Oncologists Reveals 98.9% of Physicians Experienced Cancer Drug Shortages in Last 12 Months
5. Zacks Industry Outlook Highlights: Eli Lilly, Forest Labs, ViroPharma, Novartis and United Therapeutics
6. Student of Liver And Vascular Surgery of West China Hospital of Sichuan University Addresses The 18th ILTS Annual Meeting in the United States
7. Eleven Integrated Health Systems Form Largest Private-Sector Diabetes Registry in United States
8. United Spinal To "Roll on Capitol Hill:" Voices Aim to Impact Federal Health Care Policy
9. United States ENT Devices Market Outlook to 2018 - Diagnostic Devices, Hearing Aid Devices, Hearing Implants and Others
10. Zimmer Introduces First Porous Metal Interbody Implant for Lumbar Spine in the United States
11. United Kingdom ENT Devices Market Outlook to 2018 - Diagnostic Devices, Hearing Aid Devices, Hearing Implants and Others
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... --  Pulmatrix, Inc ., (NASDAQ: PULM ), ... today that it was added to the Russell Microcap ... set of U.S. and global equity indexes on June ... for Pulmatrix," said Chief Executive Officer Robert Clarke ... in developing drugs for crucial unmet medical needs, and ...
(Date:6/23/2016)... 23, 2016  MedSource announced today that it ... software solution of choice.  This latest decision demonstrates ... to their clients by offering a state-of-the-art electronic ... establishes nowEDC as the EDC platform of choice ... clients.  "nowEDC has long been a preferred EDC ...
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... the "Pharmaceutical Excipients Market by Type (Organic Chemical ... Preservative), Formulation (Oral, Topical, Coating, Parenteral) - Global Forecast ... The global pharmaceutical excipients ... 2021 at a CAGR of 6.1% in the forecast ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... ... TopConsumerReviews.com recently awarded their highest five-star rating to Best Buy Eyeglasses, an ... United States and Canada wear eyeglasses. Once considered to be a purely functional part ... fashion statement. Even celebrities use glasses as a way of creating an iconic image—like ...
(Date:6/26/2016)... Carolina (PRWEB) , ... June 26, 2016 , ... ... of a new product that was developed to enhance the health of felines. The ... centuries. , The two main herbs in the PawPaws Cat Kidney Support ...
(Date:6/25/2016)... ... , ... Austin residents seeking Mohs surgery services, can now turn to Dr. ... Russell Peckham for medical and surgical dermatology. , Dr. Dorsey brings specialization to include ... in Mohs Micrographic Surgery completed by Dr. Dorsey was under the direction of Glenn ...
(Date:6/25/2016)... ... 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe earned ... the David Geffen School of Medicine at UCLA. He trained in Internal Medicine at ... fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the opportunity ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published June 14 ... The article goes on to state that individuals are now more comfortable seeking to ... operations such as calf and cheek reduction. The Los Angeles area medical group, Beverly ...
Breaking Medicine News(10 mins):